The field of cancer genetics has rapidly evolved to become a cornerstone of oncological research, unveiling critical molecular mechanisms that contribute to cancer initiation and progression. Recent technological advancements in genomics, coupled with an expanding knowledge base regarding genetic aberrations, offer invaluable insights that are vital for advancing targeted therapies and optimizing patient care. However, despite these advancements, challenges such as tumor heterogeneity, resistance to therapy, and the integration of these insights into effective clinical strategies remain formidable obstacles.
This Research Topic aims to update and extend our understanding of cancer genetics while exploring the crucial interface between genomic information and pharmacological applications. The series intends to catalyze innovations in drug development, refine therapeutic approaches, and facilitate the adoption of precise, genetics-based treatment protocols. By addressing pivotal issues such as drug resistance and the exploitation of genetic biomarkers for therapy customization, this issue seeks to propel the field towards more integrated and targeted treatment paradigms.
To gather further insights within this intricate domain, we welcome articles addressing, but not limited to, the following themes:
Genetic Mutations and Cancer: Key drivers and their implications in therapy targeting.
Genomic Technologies: Cutting-edge tools like NGS and CRISPR-Cas9 and their impact.
Tumor Heterogeneity: Effects on treatment strategies and disease management.
Biomarkers and Diagnostics: Roles in early detection and therapeutic precision.
Targeted Therapies: Development and challenges of genetically informed interventions.
Immunogenomics: Genetics of immune evasion and immunotherapy potentials.
Epigenetic Modifications: Therapeutic targets and pharmaceutical modulation.
Pharmacogenomics and Personalized Medicine: Tailoring treatments through genetic insights.
Translational Research: From genetic discoveries to clinical applications.
Future Directions: Innovative therapies and strategic advancements in precision medicine.
Through this comprehensive approach, the series will foster a deeper understanding of the genetic foundations of cancer and their pharmacological implications, aiming to revolutionize cancer care through scientific excellence and collaborative research efforts.
Please note: If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided. Studies related to natural compounds, herbal extracts, or traditional medicine products, are outside the scope of this Research Topic and should instead be submitted to the specialty section Ethnopharmacology. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or experimental validation, will not be included in this Research Topic.
Keywords:
Cancer Genomics, Pharmacogenomics, Targeted Therapies, Tumor Heterogeneity, Personalized Medicine
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.
The field of cancer genetics has rapidly evolved to become a cornerstone of oncological research, unveiling critical molecular mechanisms that contribute to cancer initiation and progression. Recent technological advancements in genomics, coupled with an expanding knowledge base regarding genetic aberrations, offer invaluable insights that are vital for advancing targeted therapies and optimizing patient care. However, despite these advancements, challenges such as tumor heterogeneity, resistance to therapy, and the integration of these insights into effective clinical strategies remain formidable obstacles.
This Research Topic aims to update and extend our understanding of cancer genetics while exploring the crucial interface between genomic information and pharmacological applications. The series intends to catalyze innovations in drug development, refine therapeutic approaches, and facilitate the adoption of precise, genetics-based treatment protocols. By addressing pivotal issues such as drug resistance and the exploitation of genetic biomarkers for therapy customization, this issue seeks to propel the field towards more integrated and targeted treatment paradigms.
To gather further insights within this intricate domain, we welcome articles addressing, but not limited to, the following themes:
Genetic Mutations and Cancer: Key drivers and their implications in therapy targeting.
Genomic Technologies: Cutting-edge tools like NGS and CRISPR-Cas9 and their impact.
Tumor Heterogeneity: Effects on treatment strategies and disease management.
Biomarkers and Diagnostics: Roles in early detection and therapeutic precision.
Targeted Therapies: Development and challenges of genetically informed interventions.
Immunogenomics: Genetics of immune evasion and immunotherapy potentials.
Epigenetic Modifications: Therapeutic targets and pharmaceutical modulation.
Pharmacogenomics and Personalized Medicine: Tailoring treatments through genetic insights.
Translational Research: From genetic discoveries to clinical applications.
Future Directions: Innovative therapies and strategic advancements in precision medicine.
Through this comprehensive approach, the series will foster a deeper understanding of the genetic foundations of cancer and their pharmacological implications, aiming to revolutionize cancer care through scientific excellence and collaborative research efforts.
Please note: If patient data are analyzed, a comprehensive description of the patients including sex, age, diagnostic criteria, inclusion and exclusion criteria, disease stage, therapy received, comorbidities as well as additional clinical information and assessment of clinical response/effects should be included. If genetic, proteomics, metabolomics, or other omics data are analyzed, a comprehensive description of the methods and the rationale for the selection of the specific data studied should be provided. Studies related to natural compounds, herbal extracts, or traditional medicine products, are outside the scope of this Research Topic and should instead be submitted to the specialty section Ethnopharmacology. Studies solely based on the analysis of public databases or published evidence, with no further experimental insights or experimental validation, will not be included in this Research Topic.
Keywords:
Cancer Genomics, Pharmacogenomics, Targeted Therapies, Tumor Heterogeneity, Personalized Medicine
Important Note:
All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.